Apart from PPAR dual agonist, a pan-PPAR agonist targeting PPAR alpha/delta/gamma has been developed and recently approved for use in patients with T2DM and non-alcoholic steatohepatitis in China [210]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.